News

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...